Kynurenines in the mammalian brain: when physiology meets pathology.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22678511.
- Also identified by DOI 10.1038/nrn3257 and PMC identifier 3681811.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The essential amino acid tryptophan is not only a precursor of serotonin but is also degraded to several other neuroactive compounds, including kynurenic acid, 3-hydroxykynurenine and quinolinic acid. The synthesis of these metabolites is regulated by an enzymatic cascade, known as the kynurenine pathway, that is tightly controlled by the immune system. Dysregulation of this pathway, resulting in hyper-or hypofunction of active metabolites, is associated with neurodegenerative and other neurological disorders, as well as with psychiatric diseases such as depression and schizophrenia. With recently developed pharmacological agents, it is now possible to restore metabolic equilibrium and envisage novel therapeutic interventions.
Medical subject headings
- Brain
- Kynurenine
- Nervous System Diseases
- Signal Transduction